Reduction in daytime ambulatory systolic blood pressure at two months greater with ultrasound renal denervation versus sham procedure<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 24, 2021 (HealthDay News) — Ultrasound renal denervation reduces blood pressure compared with a sham procedure among patients with hypertension resistant to a standardized triple combination pill, according to a study published online May 16 in The Lancet <\/em>to coincide with the annual meeting of the American College of Cardiology, held virtually from May 15 to 17.<\/p>\n Michel Azizi, M.D., from the Universit \u00a9 de Paris, and colleagues conducted a randomized single-blind, sham-controlled trial involving patients aged 18 to 75 years with office blood pressure of at least 140\/90 mm Hg despite three or more antihypertensive medications, including a diuretic. Patients were switched to a once-daily, fixed-dose, single pill combination of a calcium channel blocker, angiotensin receptor blocker, and thiazide diuretic. Those with daytime ambulatory blood pressure of at least 135\/85 mm Hg after four weeks of therapy were randomly assigned to either ultrasound renal denervation or a sham procedure (69 and 67 patients, respectively).<\/p>\n The researchers found that compared with the sham procedure, there was a greater reduction in daytime ambulatory systolic blood pressure at two months with renal denervation (\u00e2\u0088\u00928.0 versus \u00e2\u0088\u00923.0 mm Hg, respectively; median between-group difference, \u00e2\u0088\u00924.5 mm Hg). Among patients with complete ambulatory blood pressure data, the median between-group difference was \u00e2\u0088\u00925.8 mm Hg. There were no differences observed between the groups in safety outcomes.<\/p>\n “Follow-up of the present population for three years as well as additional studies will be important to evaluate the durability, continued safety, and long-term clinical impact of ultrasound renal denervation in patients with various forms of hypertension,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical and medical device companies, including ReCor Medical, which funded the trial. <\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n